Compare NNDM & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNDM | OABI |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.4M | 391.4M |
| IPO Year | 2015 | N/A |
| Metric | NNDM | OABI |
|---|---|---|
| Price | $1.36 | $2.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | ★ 5.2M | 526.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,437,000.00 | N/A |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 77.30 | N/A |
| 52 Week Low | $1.19 | $1.32 |
| 52 Week High | $2.32 | $2.79 |
| Indicator | NNDM | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 53.77 |
| Support Level | N/A | $1.43 |
| Resistance Level | $1.86 | $2.79 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 26.23 | 43.04 |
Nano Dimension Ltd provides industrial manufacturing solutions for the design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, and industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research, and academia, along with government organizations.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.